ISO 13485 certification
2022
2022
Strengthening of the team and a new agreement signed for larger office premises
2022
2022
Patent granted in Hong Kong for Biosensor For Male Infertility valid until 2040
2021
JUNO-Checked® Instrument Prototype Finalized
2021
2021
ULRIK NILSSON STARTS AS CFO
2021
EUROPEAN PATENT EP3768825 IS GRANTED WITH NATIONAL VALIDATION IN 16 COUNTRIES
2021
2021
Spermosens appoints Advisory Board with leading KOLs
2021
EMISSION PERIOD STARTED FOR LISTING ON SPOTLIGHT STOCKMARKET WITH ESTIMATED FIRST DAY OFF TRADING MAY 5th
2021
2021
Clinical validation studies started at Oslo Metropolitan University
2021
Application for national patent on all Spermosens target markets globally
2021
2020
Application for national patent in EU according to PACE programme for rapid entry
2020
Bull study at University in Murcia confirming JUNO as essential biomarker for male fertility
2020
2020
PRELIMINARY REPORT ON PATENTABILITY (IPRP)
European Patent Office acknowledges novelty, inventive step and industrial applicability.
2020
Spermosens becomes member of SmiLe Incubator
2020
2020
Spermosens gets laboratory facility at Medicon Village
2020
John Lempert joins as the CEO
Kush starts as the CSO2020
2020
Spermosens receives support from Innovation Skåne
2020
Spermosens moves into The Spark, Medicon Village
2020
2019
SPERMOSENS BIOSENSOR DEVELOPED
2019
Proprietary JUNO and ZP3 proteins produced
2019
2019
Spermosens receives support from Vinnova
2018
Foundation of Spermosens
2018
2018
First patent application filed
2018
JUNO reported on human oocytes
2018
2014
Discovery of JUNO in mammals
2014
Early prototype with ZP3 established
2014
2012
Kush Punyani and Prof Sudha Srivastava conceptualise a fertility testing device
